CSL Ltd

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.

The 500 million international units (IUs) will include product specifically manufactured for donation allowing for a longer shelf life and enabling more people around the world to access life-saving therapy. KING OF PRUSSIA, Pa.

CSL Behring Donates 500 Million International Units of Coagulation Factor Replacement Therapy to the World Federation of Hemophilia Humanitarian Aid Program to Help Those Living with Bleeding Disorders

MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the definitive notice of the end result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348) for USD 179.25 per share as indicated in the offer prospectus of 18 Janua

Publication of definitive end result for Vifor Pharma tender offer

MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the provisional notice of the end result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348) for USD 179.25 per share as indicated in the offer prospectus of 18 Janu

Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent

MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the definitive notice of the Interim Result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348) for USD 179.25 per share as indicated in the offer prospectus of 18 J

Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful

MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced the provisional notice of the interim result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348) for USD 179.25 per share as indicated in the offer prospectus of 18

Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent

KING OF PRUSSIA, Pa., March 2, 2022 /PRNewswire/ -- Forbes Magazine has named global biotechnology leader CSL among America's Best Employers for 2022.

Forbes Magazine Ranks Global Biotech Leader CSL Among America's Best Employers for 2022

SUMMIT, N.J., Feb. 25, 2022 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the renewal of a five-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).1 The agreement further strengthens the U.S. government's pandemic preparedness and response capability by ensuring ready production of medical countermeasures (MCMs).

Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response

BOCA RATON, Fla., Feb. 22, 2022 /PRNewswire/ -- CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, today announced a $125,000 donation to the American Red Cross to fund disaster relief across communities in the United States, including areas where plasma donors and employees live and work.

CSL Plasma Makes $125,000 Donation to American Red Cross for Disaster Relief in U.S. Communities

CSL Limited (CSLLY) CEO Paul Perreault on Q2 2022 Results - Earnings Call Transcript

SUMMIT, N.J., Feb. 7, 2022 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced an investment in a new Research and Development (R&D) facility located in Waltham, Mass.

Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology

MELBOURNE, Australia & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today published the offer prospectus regarding its public tender offer for all publicly held registered shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348), a global specialty pharmaceutical company with leadership in Iron Deficiency, Ne

CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.

MARBURG, Germany, Dec. 15, 2021 /PRNewswire/ -- CSL Behring today announced that the European Medicines Agency (EMA) has granted its approval for an accelerated assessment request for etranacogene dezaparvovec Marketing Authorisation Application (MAA). Etranacogene dezaparvovec is an investigational gene therapy for people with haemophilia B, a life-threatening bleeding disorder, and is currently being studied in the Phase 3 HOPE-B clinical trial.

EMA Grants Accelerated Assessment for CSL Behring's Haemophilia B Gene Therapy

Australian biopharma CSL Ltd (OTC: CSLLY) has agreed to acquire Vifor Pharma AG (OTC: GNHAY) for $11.7 billion (equity value) in a move to diversify its business.  The all-cash purchase at $179.25 per share represents a 40% premium on the 60-day average price of Vifor's stock as of December 1.

CSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021

ST. GALLEN, Switzerland--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, today announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CH

CSL Limited announces tender offer to acquire Vifor Pharma Ltd

SUMMIT, N.J., Dec. 7, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the relative effectiveness of FLUAD® (Influenza Vaccine, Adjuvanted), its adjuvanted trivalent vaccine (aTIV), compared with standard-dose, non-adjuvanted trivalent influenza vaccine (TIV) and standard-dose quadrivalent influenza vaccine (QIV) in reducing influenza-related outcomes over 18 influenza seasons in Italy.1 Additionally, two studies demonstrated the cost effectiveness of FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted), its adjuvanted quadrivalent seasonal influenza vaccine (aQIV) in Spain and France.2,3 These data were presented at the European Scientific Working Group on Influenza (ESWI) 8th Virtual Conference held from December 4-7, 2021.

New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults

SUMMIT, N.J., Nov. 23, 2021 /PRNewswire/ --  The FDA has granted approval of multi-dose vial presentation for AUDENZ™ to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.1 As the first-ever adjuvanted, cell-based influenza vaccine, AUDENZ™ was originally approved by the FDA in February 2020 in prefilled syringe presentation.

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

BOCA RATON, Fla., Oct. 26, 2021 /PRNewswire/ -- CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, today announced the opening of its 300th U.S. plasma center, which is located in Greenacres, Florida.

CSL Plasma Opens 300th Plasma Donation Center in United States

MELBOURNE, Australia and KING OF PRUSSIA, Pa., Oct. 18, 2021 /PRNewswire/ -- During its annual R&D investment briefing earlier today, CSL Limited (ASX:CSL; USOTC:CSLLY) highlighted progress from its novel pipeline that spans six therapeutic areas (immunology, hematology, respiratory, cardiovascular and metabolic, transplant, influenza), four scientific platforms (plasma fractionation, recombinant technology, cell and gene therapy, vaccines) and two businesses (CSL Behring and Seqirus).

Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Highlights from CSL R&D Day

KING OF PRUSSIA, Pa. and PHILADELPHIA, Sept.

Urban League of Philadelphia Names CSL's Elizabeth Walker to Board of Directors

BOCA RATON, Fla., Aug. 26, 2021 /PRNewswire/ -- CSL Plasma today announced it will provide influenza (flu) vaccination vouchers to U.S. plasma donors following the completion of two plasma donations made within a calendar month.

CSL Plasma to Provide Flu Vaccines to U.S. Plasma Donors

CSL Limited's (CSLLY) CEO Paul Perreault on Q4 2021 Results - Earnings Call Transcript

KING OF PRUSSIA, Pa., Aug. 9, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force has released an update to its guideline on diagnosis and treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

The European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force Has Strongly Recommended Subcutaneous Immunoglobulin (SCIg) for CIDP Maintenance Treatment

KING OF PRUSSIA, Pa., Aug. 3, 2021 /PRNewswire/ --  CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug. 30, 2020) for co-packaging of a convenience administration kit along with its product BERINERT, indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and pediatric patients.

FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient Convenience

KING OF PRUSSIA, Pa., June 8, 2021 /PRNewswire/ --  Global biotherapeutics leader CSL Behring today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage under Medicare Part B for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) To Be Covered Under Medicare Part B Effective July 18, Improving Access and Reducing Out-of-Pocket Costs for CIDP Patients

CSL Limited recently closed a license agreement for a haemophilia B gene therapy candidate which is positive, but there are still risks associated with competition and regulatory approvals. The company's near-term outlook is mixed, with the potential upside of increased influenza vaccine demand offset by the prospects of low plasma collection volumes.

News for CSL Ltd Stock (CSLLY)